Rafael Holdings, Inc. (NYSE:RFL) Sees Significant Increase in Short Interest

Rafael Holdings, Inc. (NYSE:RFL) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 133,570 shares, a growth of 90.8% from the June 15th total of 70,015 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average trading volume of 303,935 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Rafael

A number of large investors have recently added to or reduced their stakes in the company. Marshall Wace LLP bought a new position in shares of Rafael during the second quarter valued at about $50,000. Citadel Advisors LLC boosted its holdings in shares of Rafael by 132.3% during the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after purchasing an additional 41,335 shares during the period. Renaissance Technologies LLC grew its stake in shares of Rafael by 59.1% in the first quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock worth $111,000 after purchasing an additional 33,111 shares during the last quarter. Cable Car Capital LP bought a new stake in shares of Rafael in the second quarter worth about $173,000. Finally, Geode Capital Management LLC increased its holdings in Rafael by 25.4% during the 4th quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock valued at $526,000 after purchasing an additional 90,417 shares during the period. Institutional investors own 11.30% of the company’s stock.

Rafael Stock Performance

NYSE:RFL opened at $2.15 on Friday. The firm has a market cap of $111.90 million, a PE ratio of -3.16 and a beta of 0.29. Rafael has a fifty-two week low of $1.12 and a fifty-two week high of $3.96. The business has a 50 day moving average price of $2.07 and a 200-day moving average price of $1.55.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.